Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Early Risk of Readmission Following Hospitalization for Reversible Cerebral Vasoconstriction Syndrome
Neurol 96:e2912-e2919, Garg, A.,et al, 2021